Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Melanoma × enfortumab vedotin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Transitional Cell 21 Urinary Bladder Neoplasms 16 Ureteral Neoplasms 7 Urethral Neoplasms 3 Urologic Neoplasms 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Neoplasms 2 Neoplasm Metastasis 2 Muscle Invasive Bladder Urothelial Carcinoma 2 Metastatic Urothelial Cancer 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Advanced Bladder Cancer 2 Urothelial Cancer 1 Urachal adenocarcinoma 1 Triple Negative Breast Neoplasms 1 Salivary Gland Neoplasms 1 Renal Pelvis and Ureter Urothelial Carcinoma 1 Peripheral Nervous System Diseases 1 Penile Squamous Cell Carcinoma (PSCC) 1 Penile Neoplasms 1 Pancreatic Neoplasms 1 Non-Muscle Invasive Bladder Neoplasms 1 Muscle-invasive Bladder Cancer 1 Metastatic Urothelial Cancer and Other Malignant Solid Tumors 1 Metastatic Castration-resistant Prostate Cancer 1 Melanoma 1 Head and Neck Neoplasms 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1

Interventions

pembrolizumab 256 Nivolumab 228 Ipilimumab 208 Cyclophosphamide 125 aldesleukin 123 Interleukin-2 92 Dacarbazine 68 trametinib 66 Temozolomide 66 fludarabine 64 Vemurafenib 63 dabrafenib 59 fludarabine phosphate 56 Radiosurgery 43 sargramostim 40 Biopsy 40 Bevacizumab 39 binimetinib 38 incomplete Freund's adjuvant 37 Paclitaxel 35 Cisplatin 34 Radiotherapy 33 encorafenib 31 atezolizumab 31 cobimetinib 30 Magnetic Resonance Spectroscopy 30 Carboplatin 29 Introns 28 Specimen Handling 27 CTLA-4 Antigen 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06906822 2025-09-18

PlugIN

Grupo Español Multidisciplinar de Melanoma

Phase 2 Recruiting

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡